The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For Validation AVCT will need to prove ability to supply demand, it will take two to three months to ramp up that sort of capability, this is still a tremendous opportunity to buy into a company which will give fantastic shareholder returns in the coming months and years in both capital appreciation and returns. A great presentation which will instal confidence.
Your list is helpful in reflecting the ukrtc process. But to treat this as a fixed order with avacta on point 3 is not realistic. Avacta have done 1-5 and this is self evident from the fact that they are doing 8 right now and when complete will do 6 and 7 and 9-14. Big manufactuers doing 8 with them is a big vote of confidence in the performance of the test. Its basically so good and so important and commercially valuable that big manufacturers are setting up to do millions per week of production. Come on board Merchant. Good entry point here.
You’re right Hants, we might throw them a bone.
What has this got to do with another stock. This is purely focused on AVCT. I posted the following regarding the process to get the product to market of 9th September. I got shot down saying its wrong, when it's clear this is the process and Fincapp note and results confirm where they are. I see comments all the time saying approval/sales are due any day here and its clear from today that they are a long way off. It's not a de-ramp its just honest evaluation and if you are comfortable with where they are they good. AVCT are at stage 4 below, you could add a stage 4.5 production of validation batches.
This is the process a self test has to go through. Avct are at stage 3 i believe, so a long way to go.
1 R&D
2 Prototype
3 Initial evaluation
4 Continued performance enhancement
5 Design Freeze
6 Clinical Validation
7 CE Mark
8 Manufacturing scale up and tech transfer
9 PHE/MHRA validation
10 Approval for Professionals Use
11 Commercial roll out for professional use
12 Self test study and validation
13 Self test approval
14 Commercial roll out for individual use
That's not true PL75, they might manufacturing another company's antigen test which nobody knows how well progressed it is.
I'm not going to bother bickering with you merchant'anker, it's pointless. I'm happy with my investment, hope you're happy with yours. Oh, by the way ODX haven't got an order purely because the govt are interested in antigen testing as antibody testing is completely pointless. Awkward. Good luck and goodbye, I'm off to watch the presentation
PL75 - er not really everyone is expecting approval any day, government order any day, 100m sales a day any day. Yes you are right the market for covid will be around for many years, so there is no need for everything to be delivered today to be successful but it's not anywhere near as close as people seem to believe.
JDT - It's not a competition, the market will be big enough for any companies that can bring a POC test to market. Just about some honesty about where in the product lifecycle they are and what the chances of success are.
Hopefully the presentation will add further clarity. Popcorn at the ready.
Merchantwnker, go back to the ODX board.
7th Sep RNS:
"Avacta remains focused on the much larger opportunity of the saliva-based coronavirus antigen rapid test that we are developing with Cytiva and which is now in the process of technology transfer to our manufacturing partners. "
Today's RNS simply re-confirms everything which we already knew. Nothing has changed and nothing bad has happened - infact, everything is great - especially with the updated broker target. Clearly massive upside here within a matter of weeks.
Not nailed on, but as close to nailed on as one could reasonably expect.
Fine by me MB. It's not like there is anyone poised waiting in the wings with an equivalent or near equivalent. Anyone else who wants to play in this space will also need to go though exactly the same protocols so wont be jumping the queue. You can see what that does to your reputation - the FT article tore iAbra apart.
Happy to hold, all progressing well. The only people annoyed it is taking longer are the quick buck traders who piled in £2+ and (if they knew about it) the general public/businesses who would be able to return to some kind of normal and have a Christmas.
Did you choose your handle or is it what your friends call you
Exactly the position everyone already knew we were in. The great news is that once the tech transfer is complete they can start signing up more manufacturing partners globally. Covid is going nowhere fast:
https://www.statista.com/statistics/1103046/new-coronavirus-covid19-cases-number-worldwide-by-day/
There's an increasing realisation that it will be with us for quite some time, which means there'll be demand for the holy grail for quite some time. Anyway, thanks for the negative spin as always
So here's the bit that discloses exactly where they are in the process...... They are still at manufacturing stage, to generate tests for clinical testing in Q4. Clearly a very long way off having a test ready to market.
"We are now supporting Cytiva and our manufacturing partners to finalise technology transfer which will deliver a scaled-up production process that will generate lateral flow test devices for clinical testing. It is essential that a robust process is developed that can produce the antigen test at scale for clinical validation in Q4, and good progress is being made in this regard."